Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Markella V. Zanni, M.D.

Co-Author

This page shows the publications co-authored by Markella Zanni and Michael Lu.
Connection Strength

1.762
  1. Factors Associated with Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People with HIV on Antiretroviral Therapy. Clin Infect Dis. 2022 Mar 02.
    View in: PubMed
    Score: 0.247
  2. Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial. J Infect Dis. 2020 07 09; 222(Suppl 1):S20-S30.
    View in: PubMed
    Score: 0.221
  3. Sex Differences in Subclinical Coronary Atherosclerotic Plaque Among Individuals With HIV on Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2018 08 01; 78(4):421-428.
    View in: PubMed
    Score: 0.193
  4. Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV. Antivir Ther. 2018; 23(1):1-9.
    View in: PubMed
    Score: 0.185
  5. Application of a Novel CD206+ Macrophage-Specific Arterial Imaging Strategy in HIV-Infected Individuals. J Infect Dis. 2017 04 15; 215(8):1264-1269.
    View in: PubMed
    Score: 0.176
  6. Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection. JAMA Cardiol. 2016 07 01; 1(4):474-80.
    View in: PubMed
    Score: 0.167
  7. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014 Sep 10; 28(14):2061-70.
    View in: PubMed
    Score: 0.147
  8. Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). J Acquir Immune Defic Syndr. 2022 03 01; 89(3):349-359.
    View in: PubMed
    Score: 0.062
  9. COVID-19 Vaccination Rates in a Global HIV Cohort. J Infect Dis. 2022 02 15; 225(4):603-607.
    View in: PubMed
    Score: 0.062
  10. Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. JAMA Netw Open. 2021 06 01; 4(6):e2114923.
    View in: PubMed
    Score: 0.059
  11. Measures of Adipose Tissue Redistribution and Atherosclerotic Coronary Plaque in HIV. Obesity (Silver Spring). 2020 04; 28(4):749-755.
    View in: PubMed
    Score: 0.054
  12. Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. Am Heart J. 2019 06; 212:1-12.
    View in: PubMed
    Score: 0.050
  13. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Am Heart J. 2019 06; 212:23-35.
    View in: PubMed
    Score: 0.050
  14. Presence, Characteristics, and Prognostic Associations of Carotid Plaque Among People Living With HIV. Circ Cardiovasc Imaging. 2017 10; 10(10).
    View in: PubMed
    Score: 0.046
  15. Subclinical myocyte injury, fibrosis and strain in relationship to coronary plaque in asymptomatic HIV-infected individuals. AIDS. 2016 09 10; 30(14):2205-14.
    View in: PubMed
    Score: 0.042
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.